CSI Market
Sign In | Register

Inhibikase Therapeutics Inc (IKT) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access IKT quarterly Cash Flow →
Cash flow patterns shown here provide context for understanding Inhibikase Therapeutics Inc's ability to sustain operations and capital deployment.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-48.26
Depreciation & amortization0.06
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation15.31
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Non Cash Consulting Fees-
Non Cash P P P Loan Forgiveness-
Increase Decrease In Operating Lease Right Of Use Assets0.12
Increase Decrease In Operating Lease Liabilities0.14
Income taxes8.40
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities1.40
Increase (Decrease) in Accounts Payable0.15
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.53
Other Working Capital0.10
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-27.79
Investing Activities
Capital Expenditures-0.01
Sale of Capital Items0.00
Short-term Investments Proceeds41.60
Payments to Acquire Marketable Securities-39.09
Real Estate Investments0.00
Maturities Of Investments Marketable Securitie23.45
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development-0.44
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities2.05
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock108.46
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payment Of Employee Taxes In Connection With Stock Option Exercise-
Proceeds From Deferred Offering Costs-
Payment Of Deferred Offering Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities108.46
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-27.80
Total Cash Flow82.73
4 historic quarters locked

Sign in to unlock the full Inhibikase Therapeutics Inc cash flow history.

Sign In Create Free Account

About Inhibikase Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 26, 2026
  • Source: ikt-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-126371

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License